Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.39 |
| ▸ | CALML3 | P27482 | 3/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715178 | 0.92 | F10 (0.41) | MGLLSIGMAR1GRM2RORC | |
| SCHEMBL2715177 | 0.92 | F10 (0.41) | MGLLSIGMAR1GRM2RORC | |
| SCHEMBL9950569 | 0.88 | MAOA (0.46) | MAOAMAOBCALML3 | |
| SCHEMBL9951169 | 0.88 | F10 (0.39) | MAOAMAOBSIGMAR1CALML3GRM2 | |
| SCHEMBL9951198 | 0.88 | GPR119 (0.37) | MGLLSIGMAR1GRM2 | |
| SCHEMBL2712444 | 0.88 | F10 (0.39) | MAOAMAOBSIGMAR1CALML3GRM2 | |
| SCHEMBL10130749 | 0.86 | MAOB (0.46) | MAOAMAOBMGLLSIGMAR1CALML3 | |
| SCHEMBL12974055 | 0.81 | F10 (0.43) | MGLLSIGMAR1GRM2 | |
| SCHEMBL9951166 | 0.81 | MGLL (0.36) | MGLLSIGMAR1GRM2RORC | |
| SCHEMBL9951540 | 0.80 | MGLL (0.40) | MGLLRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | MAOA 673/4885MAOB 227/4885MGLL 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.